Online citations, reference lists, and bibliographies.
← Back to Search

Recombinant Human Growth Hormone Poly(lactic-co-glycolic Acid) Microsphere Formulation Development.

Jones, Putney, Johnson, Cleland
Published 1997 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The development of a sustained release formulation of recombinant human growth hormone (rhGH) has focused on a depot preparation using the biodegradable polymer, poly(lactic-co-glycolic acid) (PLGA), for microsphere production. These formulations have been designed to assure the maintenance of protein integrity both during the microencapsulation process and upon subsequent release in vitro and in vivo. In addition, animal models were developed to assess both the in vivo release kinetics and the potency of the released protein. These studies emphasized the importance of obtaining a correlation between the in vivo and in vitro release at an early stage of development. Juvenile rhesus monkey studies revealed that continuous rhGH administration resulted in a greater total insulin-like growth factor-I (IGF-I) response than daily rhGH administration, indicating that a continuous rhGH dose may provide comparable efficacy to daily dosing at a lower total dose of rhGH. The use of a conventional water-in-oil-in-water process yielded a triphasic release of biologically active and non-immunogenic rhGH, while the novel cryogenic process achieved a continuous release of rhGH that is biologically active and non-immunogenic. The rhGH PLGA formulation produced by the novel cryogenic process was manufactured under aseptic GMP conditions and was shown to be safe in growth hormone-deficient adults. This protein and these studies should serve as a model for the future development of PLGA formulations for therapeutic proteins.
This paper references
10.1159/000184672
Growth Hormone Therapy in Turner Syndrome
M. Ranke (1995)
10.1210/JCEM-10-5-492
Failure of hypophyseal growth hormone to produce nitrogen storage in a girl with hypophyseal dwarfism.
L. L. Bennett (1950)
10.1007/978-1-4899-1236-7_1
Stability and characterization of human growth hormone.
R. Pearlman (1993)
10.1038/nm0796-795
A month–long effect from a single injection of microencapsulated human growth hormone
O. Johnson (1996)
10.1021/AC00094A011
Conformational changes in the reversed phase liquid chromatography of recombinant human growth hormone as a function of organic solvent: the molten globule state.
S. Wičar (1994)
Wasting syndrome in AIDS: pathophysiologic mechanisms and therapeutic approaches.
Weinroth Se (1995)
10.1007/978-1-4615-1823-5_18
Design and production of single-immunization vaccines using polylactide polyglycolide microsphere systems.
J. Cleland (1995)
10.1210/JCEM-51-4-691
Role of aggregated human growth hormone (hGH) in development of antibodies to hGH.
W. Moore (1980)
10.1016/S0022-3476(94)70358-2
Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. Genentech Cooperative Study Group.
R. Fine (1994)
10.1023/A:1012031012367
The Stability of Recombinant Human Growth Hormone in Poly(lactic-co-glycolic acid) (PLGA) Microspheres
J. Cleland (2004)
10.1016/c2013-0-11606-6
The anterior pituitary
A. Tixier-vidal (1975)
10.1023/A:1012142204132
The Stabilization and Encapsulation of Human Growth Hormone into Biodegradable Microspheres
O. Johnson (2004)
10.1210/JCEM.80.8.7543114
Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients.
T. Laursen (1995)
10.1046/j.1365-2265.1996.675497.x
Growth hormone secretion in normal prepubertal children: importance of relations between endogenous secretion, pulsatility and body mass
T. Martı́n-Hernández (1996)
10.1016/S0168-3659(96)01625-2
Development of a single-shot subunit vaccine for HIV-1.
J. Cleland (1994)
10.1152/AJPENDO.1987.252.4.E549
Impact of intensive venous sampling on characterization of pulsatile GH release.
W. S. Evans (1987)
10.1016/0026-0495(95)90227-9
Defining growth hormone deficiency in adults.
K. K. Ho (1995)
The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation.
J. Cleland (1993)
10.1016/0021-9673(92)85204-7
Separation of oxidized human growth hormone variants by reversed-phase high-performance liquid chromatography. Effect of mobile phase pH and organic modifier.
G. Teshima (1992)
10.1021/JS960480L
Factors affecting the in vitro release of recombinant human interferon‐γ (rhIFN‐γ) from PLGA microspheres
J. Yang (1997)
10.1210/JCEM.74.4.1548338
Properties of spontaneous growth hormone secretory bursts and half-life of endogenous growth hormone in boys with idiopathic short stature. Genentech Collaborative Group.
Veldhuis JDP6 (1992)
10.1002/JBM.820110507
Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modification with changes in PLA/PGA copolymer ratios.
R. Miller (1977)
In vivo characterization of sustained-release formulations of human growth hormone.
H. Lee (1997)
10.1210/JCEM.76.5.8496303
Differential regulation of serum growth hormone (GH)-binding protein during continuous infusion versus daily injection of recombinant human GH in GH-deficient children.
M. Tauber (1993)
10.1016/S0300-595X(86)80008-1
4 Treatment of growth hormone deficiency
M. Ranke (1986)
10.1159/000184153
Subcutaneous growth hormone administration in growth-hormone-deficient children. Continuous plus pulsatile overnight versus single daily injection: effects on growth rate velocity.
L. Cavallo (1994)
10.1210/JCEM-70-6-1616
Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices.
J. Jørgensen (1990)
10.1021/BI00268A033
Stabilization of protein structure by sugars.
T. Arakawa (1982)
10.1016/S0939-6411(97)00065-9
Pharmacological modulation of the tissue response to implanted polylactic-co-glycolic acid microspheres
A. Daugherty (1997)
10.1136/bmj.295.6598.573
Effect of growth hormone on short normal children.
P. Hindmarsh (1987)
10.1007/978-3-7091-9450-8_3
Molecular biology of growth-hormone-secreting human pituitary tumours: biochemical consequences and potential clinical significance.
E. Adams (1996)
10.1046/J.1365-2265.1996.728550.X
Decreased plasma and extracellular volume in growth hormone deficient adults and the acute and prolonged effects of GH administration: a controlled experimental study.
J. Møller (1996)
10.1210/EDRV-12-3-189
Human growth hormone replacement therapy: pharmacological and clinical aspects.
J. Jørgensen (1991)
10.2165/00003495-199448060-00008
Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.
G. Plosker (1994)
10.1111/J.1399-3011.1994.TB00163.X
Diketopiperazine formation and N-terminal degradation in recombinant human growth hormone.
J. Battersby (1994)
10.1515/JPEM.1994.7.2.107
The Use of Recombinant Human Growth Hormone in Short Children with Chronic Renal Failure
O. Mehls (1994)
10.1126/SCIENCE.1907025
Dimerization of human growth hormone by zinc.
B. Cunningham (1991)
10.1159/000184676
Metabolic effects of GH: a rationale for continued GH treatment of GH-deficient adults after cessation of linear growth.
A. Juul (1995)
Isolation and characterization of a succinimide variant of methionyl human growth hormone.
G. Teshima (1991)
Growth hormone insensitivity syndrome (Laron syndrome): main characteristics and effects of IGF1 treatment.
J. Carel (1996)
10.1002/JBM.820190315
Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules.
G. Visscher (1985)
10.1016/S0169-409X(00)00144-7
Factors affecting short-term and long-term stabilities of proteins.
T. Arakawa (2001)
10.1126/SCIENCE.124.3235.1293
Preparation and properties of growth hormone from human and monkey pituitary glands.
C. Li (1956)
10.1002/CHIN.199503310
Formulation and Delivery of Proteins and Peptides. Design and Development Strategies.
J. Cleland (1995)
Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis.
T. Stewart (1989)
10.1016/S0168-3659(97)00075-8
Recombinant human growth hormone poly(lactic-co-glycolic acid) (PLGA) microspheres provide a long lasting effect
J. Cleland (1997)
10.1210/JCEM-68-2-469
Variability in the quantitation of circulating growth hormone using commercial immunoassays.
A. Celniker (1989)
10.1159/000124731
Zinc in the anterior pituitary of rat: a histochemical and analytical work.
O. Thorlacius-Ussing (1987)



This paper is referenced by
10.1248/CPB.52.976
Influence of manufacturing parameters on development of contraceptive steroid loaded injectable microspheres.
M. Dhanaraju (2004)
Biodegradable multiblock copolymers for drug delivery applications
R. V. Dijkhuizen-Radersma (2004)
10.1016/S0168-3659(00)00224-8
Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes.
X. Lam (2000)
10.1023/B:PHAM.0000019303.12086.d1
In Vitro/in Vivo Correlation for 14C-Methylated Lysozyme Release from Poly(Ether-Ester) Microspheres
R. van Dijkhuizen-Radersma (2004)
10.1021/bp970128t
Solvent Evaporation Processes for the Production of Controlled Release Biodegradable Microsphere Formulations for Therapeutics and Vaccines
J. Cleland (1998)
10.1002/(SICI)1097-0290(19991220)65:6<659::AID-BIT6>3.0.CO;2-9
Microencapsulation of human growth hormone within biodegradable polyester microspheres: protein aggregation stability and incomplete release mechanism.
H. Kim (1999)
10.2165/00137696-200604020-00003
Nanobiotechnology in drug delivery
N. Azad (2006)
10.3390/pr8060709
Spray freeze-drying as a solution to continuous manufacturing of pharmaceutical products in bulk
M. B. Adalı (2020)
10.2478/s11696-013-0438-1
Properties of poly(lactic acid-co-glycolic acid) film modified by blending with polyurethane
Guoquan Zhu (2013)
10.1016/S0142-9612(02)00174-6
Sustained delivery of human growth hormone from a novel gel system: SABER.
F. Okumu (2002)
10.1016/J.JCONREL.2006.02.004
Biodegradable polymeric microspheres with "open/closed" pores for sustained release of human growth hormone.
H. K. Kim (2006)
DEVELOPMENT AND CHARACTERISATION OF PHOTOCROSSLINKABLE POLY(ETHYLENE CARBONATE) ELASTOMERS FOR LOCAL PROTEIN DELIVERY
L. Cornacchione (2016)
10.1016/J.PROCBIO.2012.11.007
Shaking and stirring: Comparison of controlled laboratory stress conditions applied to the human growth hormone
J. Wiesbauer (2013)
10.1007/BF02931982
Microencapsulation methods for delivery of protein drugs
Y. Yeo (2001)
10.1248/cpb.c16-00746
Design of Highly Dispersible PLGA Microparticles in Aqueous Fluid for the Development of Long-Acting Release Injectables.
Atsushi Nakashima (2017)
10.1002/jbm.b.31239
Biodegradable and injectable paclitaxel-loaded poly(ester amide)s microspheres: fabrication and characterization.
K. Guo (2009)
10.1016/S0168-3659(02)00494-7
Sustained release of human growth hormone from microcapsules prepared by a solvent evaporation technique.
Shigeyuki Takada (2003)
10.1016/S0168-3659(03)00152-4
Carbon dioxide extraction of residual solvents in poly(lactide-co-glycolide) microparticles.
J. Herberger (2003)
10.4155/TDE.10.17
Formulation strategies for sustained release of proteins.
A. L. Lewis (2010)
2 INITIAL DEVELOPMENT OF ADJUVANTS FOR TOXOID VACCINES : 1920 s – 1940
G. Ott (2007)
10.1517/17425247.5.3.291
Lipid implants as drug delivery systems
F. Kreye (2008)
10.1002/biot.200700251
Injectable and sustained delivery of human growth hormone using chemically modified Pluronic copolymer hydrogels.
S. Park (2008)
10.1016/B978-0-12-384964-9.00011-6
Parenteral Delivery of Peptides and Proteins
H. Agrawal (2011)
10.1023/A:1010038908767
Optimization of Preparation Techniques for Poly(Lactic Acid-Co-Glycolic Acid) Nanoparticles
D. Birnbaum (2000)
10.1016/j.ijpharm.2009.06.014
Biopharmaceutical characterisation of insulin and recombinant human growth hormone loaded lipid submicron particles produced by supercritical gas micro-atomisation.
S. Salmaso (2009)
10.1016/j.ijpharm.2008.11.017
Encapsulated zinc salt increases the diffusion of protein through PLG films.
S. Fredenberg (2009)
10.1007/978-1-4614-0554-2_9
In Situ Forming Systems (Depots)
J. Wright (2012)
10.22037/IJPR.2011.958
Preparing Poly (Lactic-co-Glycolic Acid) (PLGA) Microspheres Containing Lysozyme-Zinc Precipitate Using a Modified Double Emulsion Method
Nastaran Nafissi Varcheh (2011)
10.1201/9781420039832.CH6
Parenteral Controlled Delivery and Pharmacokinetics of Therapeutic Peptides and Proteins
A. Banga (2005)
10.1016/S0378-5173(03)00379-X
Hydrolytic degradation of poly(lactide-co-glycolide) films: effect of oligomers on degradation rate and crystallinity.
G. Schliecker (2003)
10.1002/adma.201100679
Facile engineering of biocompatible materials with pH-modulated degradability.
Jianxiang Zhang (2011)
10.1016/j.jconrel.2014.09.003
Microencapsulation of protein drugs for drug delivery: strategy, preparation, and applications.
G. Ma (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar